DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

NCT06805305 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma (GBM)

Interventions

BIOLOGICAL: DOC1021
PROCEDURE: Tumor resection
DRUG: Temodar (Temozolomide)
RADIATION: SOC cranial radiation

Sponsor

Diakonos Oncology Corporation